 SEATTLE, WA and VANCOUVER, BC ACCESSWIRE May 13, 2021 Achieve Life Sciences, Inc. NASDAQ:ACHV, a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced first quarter 2021 financial results and provided an update on the cytisinicline clinical development program. Recent Events Highlights Provided update on the Phase 3 ORCA-2 clinical trial evaluating the efficacy and safety of 3.0 mg cytisinicline dosed 3 times daily compared to placebo in 750 adult smokers at 17 clinical sites in the United States Published Phase 2b ORCA-1 safety, efficacy, and compliance results in Nicotine and Tobacco Research Announced the appointment of Dr. Bridget Martell and Dr. Cindy Jacobs to Achieves Board of Directors Published RAUORA Head-to-Head Non-Inferiority Clinical Trial Comparing Cytisinicline and Chantix varenicline in Addiction In the first quarter, weve seen great interest and increased momentum in the ORCA-2 trial and look forward to completing enrollment by the middle of the year, commented John Bencich, Chief Executive Officer of Achieve. 